^
    BIOMARKER:

    MYC rearrangement + BCL2 rearrangement

    i
    Other names: MYC, bHLHe39, c-Myc, MYCC, V-myc avian myelocytomatosis viral oncogene homolog, BCL2, Bcl-2, PPP1R50, B-cell CLL/lymphoma 2
    Entrez ID:
    4609; 596
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    MYC rearrangement + BCL2 rearrangement
    Lymphoma
    venetoclax + DUP 785
    Sensitive: D – Preclinical
    EHA 2022 - 2 weeks - (New D)
    MYC rearrangement + BCL2 rearrangement
    Diffuse Large B Cell Lymphoma
    lisocabtagene maraleucel
    Sensitive: A2 - Guideline
    MYC rearrangement + BCL2 rearrangement
    Diffuse Large B Cell Lymphoma
    lenalidomide
    Sensitive: B - Late Trials
    MYC rearrangement + BCL2 rearrangement
    Diffuse Large B Cell Lymphoma
    cytarabine + methotrexate
    Resistant: C3 – Early Trials
    MYC rearrangement + BCL2 rearrangement
    Diffuse Large B Cell Lymphoma
    rituximab
    Resistant: C3 – Early Trials
    MYC rearrangement + BCL2 rearrangement
    Lymphoma
    lisocabtagene maraleucel
    Sensitive: C3 – Early Trials
    MYC rearrangement + BCL2 rearrangement
    NHL
    ibrutinib
    Sensitive: C3 – Early Trials
    MYC rearrangement + BCL2 rearrangement
    Follicular Lymphoma
    EPOCH-R
    Sensitive: C3 – Early Trials
    MYC rearrangement + BCL2 rearrangement
    Follicular Lymphoma
    R-DHAP
    Sensitive: C3 – Early Trials
    MYC rearrangement + BCL2 rearrangement
    Diffuse Large B Cell Lymphoma
    lenalidomide + zanubrutinib
    Sensitive: C3 – Early Trials
    MYC rearrangement + BCL2 rearrangement
    Diffuse Large B Cell Lymphoma
    loncastuximab tesirine
    Sensitive: C3 – Early Trials
    MYC rearrangement + BCL2 rearrangement
    Diffuse Large B Cell Lymphoma
    C-RICE
    Sensitive: C3 – Early Trials
    MYC rearrangement + BCL2 rearrangement
    Diffuse Large B Cell Lymphoma
    IACS-010759
    Sensitive: D – Preclinical
    MYC rearrangement + BCL2 rearrangement
    Diffuse Large B Cell Lymphoma
    ibrutinib
    Resistant: D – Preclinical
    MYC rearrangement + BCL2 rearrangement
    NHL
    ibrutinib + alemtuzumab
    Sensitive: D – Preclinical
    MYC rearrangement + BCL2 rearrangement
    Lymphoma
    HZX-02-059
    Sensitive: D – Preclinical
    MYC rearrangement + BCL2 rearrangement
    Diffuse Large B Cell Lymphoma
    venetoclax
    Sensitive: D – Preclinical
    MYC rearrangement + BCL2 rearrangement
    Diffuse Large B Cell Lymphoma
    copanlisib
    Sensitive: D – Preclinical